• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Nemolizumab effective in reducing pruritis in atopic dermatitis

bySze Wah Samuel ChanandDeepti Shroff Karhade
July 9, 2020
in Chronic Disease, Dermatology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this study, nemolizumab with topical agents and oral antihistamines when compared to topical agents and oral antihistamines alone reduced pruritis in atopic dermatitis patients

2. Among patients in the nemolizumab group, eczema area, quality of life and insomnia improved when compared with placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The use of an interleukin-31 receptor antibody, nemolizumab, has been shown in previous studies to reduce inflammation and epidermal-barrier disruption in atopic dermatitis, which can reduce pruritis. The purpose of this trial was to evaluate the efficacy and safety of the addition of nemolizumab to concomitant topical agents and oral antihistamines for patients with moderate-to-severe pruritis, refractory to topical agents. The results of the study demonstrated that the addition of nemolizumab significantly reduced the pruritis visual-analogue scale (VAS) score after 16 weeks of treatment. Other measurements of quality of life were also significantly improved with nemolizumab such as improvement in the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and the Insomnia Severity Index (ISI). The main safety profile difference was an increased incidence of injection-related reactions compared to placebo. However, several limitations caution the generalizability of the study. This included the inclusion of only Japanese patients, the short duration of follow-up and the inclusion of only patients above the age of 13 years which excluded an important cohort with atopic dermatitis.

Click to read the study, published today in NEJM

Relevant Reading: IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity

In-Depth [randomized controlled trial]: This 16-week, double-blind, phase 3 trial included 143 Japanese patients with atopic dermatitis, moderate-to-severe pruritis and an inadequate response to topical agents and oral antihistamines. To be included in the study, patients had to be at least 13 years of age and have an inadequate pruritic response to topical glucocorticoids, topical calcineurin inhibitors and oral antihistamines. Patients were randomly assigned in a 2:1 ratio to receive nemolizumab or placebo, with both groups receiving topical agents and oral antihistamines. The primary efficacy endpoint demonstrated that the percent change in pruritis VAS score was -42.8% in the treatment group compared to -21.4% in placebo (95% CI -30.2 to -12.7). Secondary endpoints showed nemolizumab improved the EASI score (-45.9 vs. -33.2 [95% CI -26.6 to -11.9]), increased the percentage of patients with a DLQI score of ≤4 (17% difference [95% CI 2 to 31]), and increased the percentage of patients with an ISI score of ≤7 (33% difference [95% CI 17 to 48]). The most commonly reported adverse event was worsening atopic dermatitis which was present in 24% of the treatment group and 21% in placebo. Cytokine abnormalities such as an increased thymus and activation-regulated chemokine level was observed only in the treatment group but was not associated with worsening atopic dermatitis. Notably, 8% of the nemolizumab group had injection-related reactions compared to 3% in placebo.

RELATED REPORTS

#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis

Severe atopic dermatitis associated with symptoms of depression and internalizing behaviors in children

#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atopic dermatitisEczemainterleukin-31nemolizumabpruritis
Previous Post

Nurse-administered interventions in the community may not reduce the rate of first fall injury

Next Post

Early life cognitive enrichment associated with decreased Alzheimer’s pathology and cognitive decline

RelatedReports

#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis
StudyGraphics

#VisualAbstract Dupilumab may contribute to ocular surface disease in patients with atopic dermatitis

September 10, 2021
Topical pimecrolimus use for atopic dermatitis not linked to malignancy
Dermatology

Severe atopic dermatitis associated with symptoms of depression and internalizing behaviors in children

September 6, 2021
#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis
StudyGraphics

#VisualAbstract New RCT (JADE TEEN) shows efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis

August 26, 2021
#VisualAbstract: Annual screening for ovarian cancer does not significantly reduce mortality
StudyGraphics

#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;

June 24, 2021
Next Post

Early life cognitive enrichment associated with decreased Alzheimer's pathology and cognitive decline

Early life cognitive enrichment associated with decreased Alzheimer’s pathology and cognitive decline

Early life cognitive enrichment associated with decreased Alzheimer's pathology and cognitive decline

Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography

2 Minute Medicine Rewind July 13, 2020

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.